Know Cancer

forgot password

A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer

Phase 3
18 Years
Open (Enrolling)
Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity

Thank you

Trial Information

A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer


Phase III trial of induction therapy with docetaxel followed by chemoradiotherapy versus
chemoradiotherapy alone in patients with nodal stage N2 or N3 head and neck cancer



- To determine the effect on overall survival when induction chemotherapy is administered
prior to chemoradiotherapy in patients with N2 or N3 disease.


- To determine the effect of induction chemotherapy when administered prior to
chemoradiotherapy on distant failure-free survival, failure pattern, progression free
survival and quality of life.


- After eligibility is confirmed, patients will be randomized to one of two treatment

Arm A - Induction + chemoradiotherapy

Arm B - Chemoradiotherapy alone

- Induction therapy: Two 21-day cycles of chemotherapy consisting of docetaxel (day 1),
cisplatin (day 1), and 5-fluorouracil (days 1-5). Total duration of 6 weeks.

- Chemoradiotherapy: Five 14-day cycles of docetaxel (day 1), 5-fluorouracil (day 0-4),
and hydroxyurea (days 0-4) with twice daily radiation (days 1-5). Total duration of 10

- All patients will undergo surgical evaluation after chemoradiation for possible neck

- Upon completion of treatment, patients will be monitored every three months during the
first year, every six months during the second and third years, and annually
thereafter, up to five years.

- Patients will be followed for Quality of Life (QOL) during the course of treatment, as
well as annually thereafter, up to five years.


- An expected sample size of 400 patients will be enrolled for this study (200 per
treatment arm).

Inclusion Criteria:

- Age 18 years or older

- Histologically or cytologically confirmed diagnosis of squamous cell or poorly
differentiated carcinomas of the head and neck (excluding lip), or lymphoepithelioma

- No prior chemotherapy or radiotherapy

- Prior surgical therapy will consist only of incisional or excisional biopsy, and
organ sparing procedures such as debulking of airway-compromising tumors or neck
dissection in a patient with an existing primary tumor

- Karnofsky performance status of >= 70%

- Intact organ and bone marrow function

- Obtained informed consent

Exclusion Criteria:

- Demonstration of metastatic disease (i.e. M1 disease).

- Patients with a history of severe allergic reaction to docetaxel or other drugs
formulated with polysorbate 80. History of allergic reactions attributed to compounds
of similar chemical or biologic composition to cisplatin, 5-fluorouracil, or

- Other coexisting malignancies or malignancies diagnosed within the previous 3 years
with the exception of basal cell carcinoma, cervical cancer in situ, and other
treated malignancies with no evidence of disease for at least 3 years.

- Prior surgical therapy other than incisional or excisional biopsy and organ-sparing
procedures such as debulking of airway-compromising tumors or neck dissection in a
patient with an unknown primary tumor. Any non-biopsy procedure must have taken place
less than 3 months from initiating protocol treatment.

- Incomplete healing from previous surgery

- Pregnancy or breast feeding (men and women of child-bearing potential are eligible
but must consent to using effective contraception during therapy and for at least 3
months after completing therapy)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure (CHF), unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements

- Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any
history of clinically significant CHF are excluded. The exclusion of patients with
active coronary artery disease will be at the discretion of the attending physician.

- Uncontrolled active infection unless curable with treatment of their cancer.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall survival

Outcome Time Frame:


Safety Issue:


Principal Investigator

Everett E. Vokes, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Chicago


United States: Institutional Review Board

Study ID:




Start Date:

November 2004

Completion Date:

August 2013

Related Keywords:

  • Cancer of the Pharynx
  • Cancer of the Larynx
  • Cancer of the Nasal Cavity
  • Paranasal Sinus Neoplasms
  • Cancer of the Oral Cavity
  • Cancer of the Pharynx (Nasopharynx, Oropharynx, Hypopharynx)
  • Cancer of the Nasal Cavity and Paranasal Sinuses
  • Neoplasms
  • Laryngeal Neoplasms
  • Head and Neck Neoplasms
  • Paranasal Sinus Neoplasms
  • Pharyngeal Neoplasms



Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Rush University Medical Center Chicago, Illinois  60612-3824
University of Tennessee Cancer Institute Memphis, Tennessee  38103
Evanston Northwestern Healthcare Evanston, Illinois  60201
University of Minnesota Minneapolis, Minnesota  55455
Northwestern University Chicago, Illinois  60611
Henry Ford Health System Detroit, Michigan  48202
Weiss Memorial Hospital Chicago,, Illinois  60640
The University of Chicago Chicago, Illinois  60637
University of Kansas Cancer Center Kansas City, Kansas  66160
Fort Wayne Medical Oncology/Hematology Inc. Fort Wayne, Indiana  46815
USC University of Southern California Keck School of Medicine Los Angeles, California  90033
UM Sylvester Comprehensive Cancer Center Miami, Florida  33136
Joliet Oncology Hematology Associates Joliet, Illinois  60435
AP&S Clinic, LLC Terre Haute, Indiana  47807
Oncology Care Associates PLLC St. Joseph, Michigan  49085
Kansas City VA Medical Center Kansas City, Missouri  64128
Roger Maris Cancer Center Fargo, North Dakota  58122
UT Health Science Center at San Antonio San Antonio, Texas  78258
Oncology Alliance Milwaukee, Wisconsin  53215